Biological & physiological aspects of action of insulin-like growth factor peptide family

Indian Journal of Medical Research

Volumn 125, Issue 4, 2007, Pages 511-522

  Pavelić, Jasminka ^a   Matijević, Tanja ^a   Knežević, Jelena ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

Cancer treatment strategies; Growth factors; Insulin like; Oncogenes; Tumours

Indexed keywords

CELL SURFACE RECEPTOR; INSULIN RECEPTOR; LIGAND; MITOGENIC AGENT; PEPTIDE HORMONE; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ANCHORAGE INDEPENDENT GROWTH; APOPTOSIS; AUTOCRINE EFFECT; BREAST CANCER; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL PROTECTION; COLORECTAL CANCER; DRUG TARGETING; ENDOMETRIUM CANCER; HUMAN; INTERNALIZATION; LUNG CANCER; ONCOGENE; PARACRINE SIGNALING; PHENOTYPE; PROSTATE CANCER; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR SUPPRESSOR GENE;

ANIMALS; GROWTH HORMONE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; NEOPLASMS; RECEPTORS, SOMATOMEDIN; SIGNAL TRANSDUCTION; SOMATOMEDINS;

EID: 34547134937     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Salmon Jr WD, Daughaday WH. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 1957; 49: 825-36.
2. Dulak NC, Temin HM. A partially purified polypeptide fraction from rat liver cell conditioned medium with multiplication-stimulating activity for embryo fibroblasts. J Cell Physiol 1973; 8: 153-60.
3. Froesch ER, Burgi H, Ramseier EB, Bally P, Labhart A. Antibody-suppressible and nonsuppressible insulin-like activities in human serum and their physiologic significance. J Clin Invest 1963; 42: 1816-34.
4. Rinderknecht E, Humbel RE. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 1978; 253: 2769-76.
5. Denley A, Cosgrove LJ, Booker GW, Wallace JC, Forbes BE. Molecular interactions of the IGF system. Cytokine Growth Factor Rev 2005; 16: 421-39.
6. www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene&cmd= search&term=IGF+2. Accessed on September 20, 2005.
7. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4: 505-18.
8. Tang SH, Yang DH, Huang W, Zhou M, Zhou HK, Lu XH, et al. Differential promoter usage for insulin-like growth factor-II gene in Chinese hepatocellular carcinoma with hepatitis B virus infection. Cancer Detect Prev 2006; 30: 192-203.
9. Kiess W, Yang Y, Kessler U, Hoeflich A. Insulin-like growth factor II (IGF-II) and the IGF-II/mannose-6-phosphate receptor: the myth continues. Horm Res 1994; 41: 66-73.
10. Carboni JM, Lee AV, Hadsell DL, Rowley BR, Lee FY, Bol DK, et al. Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res 2005; 65: 3781-7.
11. Kornfeld S. Structure and function of the mannose-6-phosphate/insulin like growth factor II receptors. Annu Rev Biochem 1992; 61: 307-30.
12. Clemmons DR. Use of mutagenesis to probe IGF-binding protein structure/ function relationships. Endocr Rev 2001; 22: 800-17.
13. www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene&cmd= search&term=IGF+binary+protein. Accessed on September 20, 2005.
14. Ricort JM. Insulin-like growth factor binding protein (IGFBP) signaling. Growth Horm IGF Res 2004; 14: 277-86.
15. Lelbach A, Muzes G, Feher J. The insulin-like growth factor system: IGFs, IGF-binding proteins and IGFBP-proteases. Acta Physiol Hung 2005; 92: 97-107.
16. Yu H, Rohan T. Role of insulin like growth factors family in cancer development and progression. J Natl Cancer Inst 2000; 92: 1472-89.
17. Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE, Schernhammer ES, et al. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer 2006; 13: 583-92.
18. Pavelić K, Slijepčević M, Pavelić J, Ivid J, Audy-Jurković S, Pavelić ZP, et al. Growth and treatment of Ehrlich tumor in mice with alloxan-induced diabetes. Cancer Res 1979; 39: 1807-13.
19. Pavelić K, Ferle-Vidović A, Osmak M, Vuk-Pavlović S. Synthesis of immunoreactive insulin in vitro by aplastic mammary carcinoma preconditioned in diabetic mice. J Natl Cancer Inst 1981; 67: 687-8.
20. Pavelić K, Bolanča M, Većek N, Pavelić J, Marotti T, Vuk-Pavlović S. Carcinomas of the cervix and corpus uteri in humans: stage-dependent blood levels of substance(s) immunologically cross-reactive with insulin. J Natl Cancer Inst 1982; 68: 891-4.
21. Pavelić K, Spaventi Š, Glunčić V, Matejčić A, Pavićić D, Karapand•a N, et al. The expression and role of insulin-like growth factor II in malignant hemangiopericytomas. J Mol Med 1999; 77: 865-9.
22. Sporn MB, Todaro GJ. Autocrine secretion and malignant transformation of cells. N Engl J Med 1980; 303: 878-80.
23. Pavelić K. Aplastic carcinoma in diabetic mice: hyperglycemia-suppressed proliferation rate and insulin synthesis by tumor cells. J Natl Cancer Inst 1979; 62: 139-41.
24. Pavelić K, Čabrijan T, Hrašćan R, Vrkljan M, Lipovac M, Kapitanović S, et al. Molecular pathology of heman giopericytomas accompanied by severe hypoglycemia: oncogenes, tumor-suppressor genes and the insulin-like growth factor family. J Cancer Res Clin Oncol 1998; 124: 307-14.
25. Pavelić J, Pavelić Lj, Karad•a J, Kri•anać Š, Unušić J, Spaventi Š, et al. Insulin-like growth factor family and combined antisense approach in therapy of lung carcinoma. Mol Med 2002; 8: 149-57.
26. Pavelić K, Kolak T, Kapitanović S, Radošević S, Spaventi Š, Krušlin B, et al. Gastric cancer: the role of insulin-like growth factor 2 (IGF-2) and its receptors (IGF IR and M6-P/IGF-2R). J Pathol 2003; 201: 430-8.
27. Pavelić J, Kri•anac Š, Kapitanović S, Pavelić Lj, Samar•ija M, Pavièić F, et al. The consequences of insulin-like growth factor/receptors dysfunction in lung cancer. Am J Respir Cell Mol Biol 2005; 32: 65-71.
28. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363: 1346-53.
29. Renehan AG, Jones J, Potten CS, Shalet SM, O'Dwyer ST. Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br J Cancer 2000; 83: 1344-50.
30. Larsson O, Girnita A, Girnita L. Role of insulin-like growth factor I receptor signalling in cancer. Br J Cancer 2005; 92: 2097-101.
31. Oka Y, Waterland RA, Killian JK, Nolan CM, Jang HS, Tohara K, et al. M6P/IGF2R tumor suppressor gene mutated in hepatocellular carcinomas in Japan. Hepatology 2002; 35: 1153-63.
32. Jamieson TA, Brizel DM, Killian JK, Oka Y, Jang HS, Fu X, et al. M6P/IGF2R loss of heterozygosity in head and neck cancer associated with poor patients prognosis. BMC Cancer 2003; 3: 4.
33. Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM, et al. An anti-insulin-like growth factor-I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003; 63: 5073-83.
34. Feng Y, Zhu Z, Xiao X, Choudhry V, Barrett JC, Dimitrov DS. Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol Cancer Ther 2006; 5: 114-20.
35. Yee D. Targeting insulin-like growth factor pathways. Br J Cancer 2006; 94: 465-8.
36. Perona R. Cell signaling: growth factors and tyrosine kinase receptors. Clin Transl Oncol 2006; 8: 77-82.
37. Ho MN, Delgado CH, Owens GA, Steller MA. Insulin-like growth factor-II participates in the biphasic effect of a gonadotropin-releasing hormone agonist on ovarian cancer cell growth. Fertil Steril 1997; 67: 870-6.
38. Manetta A, Gamboa-Vujicic G, Paredes P, Emma D, Liao S, Leong L, et al. Inhibition of growth of human ovarian cancer in nude mice by luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75). Fertil Steril 1995; 63: 282-7.
39. Kleinman D, Roberts CT Jr, LeRoith D, Schally AV, Levy J, Sharoni Y. Regulation of endometrial cancer cell growth by insulin-like growth factors and luteinizing hormonereleasing hormone antagonist SB-75. Regul Pept 1993; 48: 91-8.
40. Hershkovitz E, Marbach M, Bosin E, Levy J, Roberts CT Jr, LeRoith D, et al. Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factors. J Clin Endocrinol Metab 1993; 77: 963-8.
41. Pollak MN, Schally AV. Mechanisms of antineoplastic action of somatostatin analogues. Proc Soc Exp Biol Med 1998; 217: 143-52.
42. Szereday Z, Schally AV, Varga JL, Kanashiro CA, Herbert F, Armatis P, et al. Antagonists of growth hormone releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma. Cancer Res 2003; 63: 7913-9.
43. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 2002; 23: 623-46.
44. Csernus VJ, Schally AV, Kiaris H, Armatis P. Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. Proc Natl Acad Sci USA 1999; 96: 3098-103.
45. Pollak M, Richard M. Suramin blockade of insulin like growth factor I-stimulated proliferation of human osteosarcoma cells. J Natl Cancer Inst 1990; 82: 1349-52.
46. Kaleko M, Rutter WJ, Miller AD. Overexpression of the human insulin like growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol 1990; 10: 464-73.
47. Lahm H, Amstad P, Wyniger J, Yilmaz A, Fischer JR, Schreyer M, et al. Blockade of the insulin-like growth factor-I receptor inhibits growth of human colorectal cancer cells: evidence of a functional IGF-II-mediated autocrine loop. Int J Cancer 1994; 58: 452-9.
48. Macaulay VM, Everard MJ, Teale JD, Trott PA, Van Wyk JJ, Smith IE, et al. Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumors. Cancer Res 1990; 50: 2511-7.
49. Arteaga CL. Interference of the IGF system as a strategy to inhibit breast cancer growth. Breast Cancer Res Treat 1992; 22: 101-6.
50. Brunetti CR, Burke RL, Kornfeld S, Gregory W, Masiarz FR, Dingwell KS, et al. Herpes simplex virus glycoprotein D acquires mannose 6-phosphate residues and binds to mannose 6- phosphate receptors. J Biol Chem 1994; 269 17067-74.